⚠ AI-Generated

The summary below was generated by an AI language model and may contain errors or omissions. All other content on this page is deterministically extracted from the original SEC EDGAR filing.

Biogen removed its COVID-19 pandemic risk disclosure, indicating the company no longer views this as a material threat to operations. Seven risks underwent substantive modifications, including expanded language on tax rate volatility, emerging risks from social media and AI platforms, product revenue concentration, environmental compliance obligations, and manufacturing facility development. These changes reflect Biogen's shift from pandemic-related concerns toward evolving regulatory, technological, and operational risks.

Classification is based on semantic text similarity scoring and may include approximations. “No match” means no high-confidence textual match was found — not necessarily that a section was removed.

🔴 No Match in Current Filing The ongoing COVID-19 pandemic and other global health outbreaks may, directly or indirectly, adversely affect our business, results of operations and financial condition. 🔒

🟡 Modified Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts. 🔒

🟡 Modified The increasing use of social media platforms and artificial intelligence based software presents new risks and challenges. 🔒

🟡 Modified We are substantially dependent on revenue from our products. 🔒

🟡 Modified Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury. 🔒

🟡 Modified We built a large-scale biologics manufacturing facility and are building a gene therapy manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped. 🔒

🟡 Modified A breakdown or breach of our information systems could subject us to liability or interrupt the operation of our business. 🔒

🟡 Modified Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives. 🔒

8 changes in this historical filing

Historical year-over-year comparisons (2024 vs 2023 and earlier) are available on the Pro plan.

Get full access — from $29/month Already a Pro subscriber? View full diff →